| Literature DB >> 35104058 |
Mélanie Prague1,2, Marc Lavielle3.
Abstract
The success of correctly identifying all the components of a nonlinear mixed-effects model is far from straightforward: it is a question of finding the best structural model, determining the type of relationship between covariates and individual parameters, detecting possible correlations between random effects, or also modeling residual errors. We present the Stochastic Approximation for Model Building Algorithm (SAMBA) procedure and show how this algorithm can be used to speed up this process of model building by identifying at each step how best to improve some of the model components. The principle of this algorithm basically consists in "learning something" about the "best model," even when a "poor model" is used to fit the data. A comparison study of the SAMBA procedure with Stepwise Covariate Modeling (SCM) and COnditional Sampling use for Stepwise Approach (COSSAC) show similar performances on several real data examples but with a much reduced computing time. This algorithm is now implemented in Monolix and in the R package Rsmlx.Entities:
Mesh:
Year: 2022 PMID: 35104058 PMCID: PMC8846636 DOI: 10.1002/psp4.12742
Source DB: PubMed Journal: CPT Pharmacometrics Syst Pharmacol ISSN: 2163-8306
FIGURE 1Scheme of the Stochastic Approximation for Model Building Algorithm (SAMBA)
FIGURE 2Step‐by‐step Stochastic Approximation for Model Building Algorithm (SAMBA) procedure on the remifentanil example with six covariates (SEX, logAGE, logBSA, logHT, logLBM, and logWT) and six model parameters (Cl, Q2, Q3, V1, V2 and V3). For each selection (covariate, correlation, and error model), the three best models in term of corrected Bayesian Information Criteria (BICc) are displayed. Non selected models are in white, newly accepted models are in darker grey, and models which have been already accepted at previous run are in lighter grey
Comparison of the SAMBA procedure with the SCM and COSSAC procedure on 10 representative datasets
| Dataset | Characteristics | SCM | COSSAC | SAMBA |
| ||||
|---|---|---|---|---|---|---|---|---|---|
| #Runs | Final Model | #Runs | Final Model 1 | #Runs | Final Model | SAMBA‐SCM | SAMBA‐COSSAC | ||
| Warfarin | 32 ind. ‐ 247 obs. | 44 | logtWt ‐ | 4 | Identical | 2 | Identical | 0 | 0 |
| Linear PK | 4 param. ‐ 3 cov. | logtAge ‐ | |||||||
| 4 re ‐ 1 outcome | |||||||||
| Remifentanil | 65 ind. ‐ 1992 obs. | 295 | logLBM – | 13 | logLBM ‐ | 4 | logLBM ‐ | 0.8 | 0.5 |
| Linear PK | 6 param. ‐ 6 cov. | logAGE ‐ | logAGE ‐ | logAGE ‐ | |||||
| 4 re ‐ 1 outcome | logBSA ‐ | logBSA ‐ | logBSA ‐ | ||||||
| logHT ‐ | |||||||||
| SEX ‐ | SEX ‐ | ||||||||
| Theophylline | 12 ind. ‐ 20 obs. | 12 | logtWEIGHT ‐ | 4 | Identical | 2 | Identical | 0 | 0 |
| Linear PK | 3 param. ‐ 2 cov. | ||||||||
| 4 re ‐ 1 outcome | |||||||||
| Quinidine | 136 ind. ‐ 361 obs. | 22 | none | 11 | Identical | 1 | Identical | 0 | 0 |
| Sparse PK | 3 param. ‐ 2 cov. | ||||||||
| 3 re ‐ 1 outcome | |||||||||
| Tobramycin | 97 ind. ‐ 322 obs. | 22 | logCLCR ‐ | 6 | logCLCR ‐ | 2 | logCLCR ‐ | 4.2 | 4.2 |
| Sparse PK | 3 param. ‐ 2 cov. | logWT ‐ | logWT ‐ | logWT ‐ | |||||
| 2 re ‐ 1 outcome | |||||||||
| Theophylline | 18 ind. ‐ 362 obs. | 98 | logWT ‐ | 8 | logWT ‐ | 6 | logWT ‐ | −11.7 | −27 |
| Ext. Rel. | 7 param. ‐ 3 cov. | logAGE ‐ | logAGE ‐ | ||||||
| Linear PK | 7 re ‐ 1 outcome | logHT ‐ | |||||||
| Warfarin | 32 ind. ‐ 247+232 obs. | 92 | logWT ‐ | 10 | logWT ‐ | 2 | logWT ‐ | −1.4 | −1.4 |
| PK/PD | 8 param. ‐ 3 cov. | logAGE ‐ | |||||||
| Joint | 8 re ‐ 2 outcomes | ||||||||
| Cholesterol | 200 ind. ‐ 1044 obs. | 12 | logAGE ‐ | 5 | logAGE ‐ | 2 | logAGE ‐ | 13.5 | 13.5 |
| Disease | 2 param. ‐ 2 cov. | SEX ‐ | SEX ‐ | ||||||
| Progression | 2 re ‐ 1 outcome | ||||||||
| Alzheimer | 896 ind. ‐ 3707 obs. | 73 | APOE ‐ | 8 | APOE ‐ | 2 | APOE ‐ | 6 | 1.5 |
| Sparse PK | 2 param. ‐ 7 cov. | logAGE ‐ | logAGE ‐ | logAGE ‐ | |||||
| 2 re ‐ 1 outcome | logBMI ‐ | logBMI ‐ | |||||||
| logWT ‐ | logWT ‐ | logWT ‐ | |||||||
| Tranexamic | 166 ind. ‐ 817 obs. | 298 | GROUP ‐ | 12 | Identical | 2 | Identical | 0 | 0 |
| PK | 4 param. ‐ 10 cov. | logBMI ‐ Cl | |||||||
| 4 re ‐ 1 outcome | logCOCK ‐ Cl | ||||||||
| logLBW ‐ Q | |||||||||
| logWeight ‐ V2 | |||||||||
Differences of variable selection between different methods are highlighted in bold.
The number of runs is defined as the number of time the estimation and the simulation steps are performed (which is the most time‐consuming).
Performance of the SAMBA algorithm for the selection of the covariate model in a simulation study using a one‐compartment PK model
| Covariates |
| Monolix | ||||
|---|---|---|---|---|---|---|
|
|
|
|
|
|
| |
|
| 2 | 100 | 100 | 2 | 100 | 100 |
|
| 0 | 1 | 100 | 0 | 1 | 100 |
|
| 1 | 2 | 1 | 2 | 2 | 1 |
|
| 0 | 3 | 4 | 0 | 3 | 4 |
|
| 0 | 1 | 1 | 1 | 2 | 1 |
One hundred datasets of 100 individuals with 11 observations each have been generated. True model includes an effect of on and and an effect of on . The percentages of times (over 100 replicates) each covariate‐parameter relationship is selected in the final model are displayed. Implementation of SAMBA in Rsmlx and Monolix are compared.
Abbreviations: Cl, linear elimination; ka, absorption rate constant; PK, pharmacokinetic; SAMBA, Stochastic Approximation for Model Building Algorithm; V, volume.